Dacomitinib Anhydrous: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Dacomitinib Anhydrous. Educational only — not medical advice.
Labeled uses
VIZIMPRO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test [see Dosage and Administration (2.1) ] .
Source: FDA labeling via NIH DailyMed (set 4ab27d2f…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.